Interferon

Interferons (IFNs) are a group of secreted cytokines—signaling proteins that allow cells to communicate during immune responses. They are particularly important in defense against viruses, but also regulate inflammation, immune-cell activity, and cell growth. Rather than directly destroying viruses, interferons bind to receptors on responsive cells and alter gene expression, establishing an antiviral state and coordinating other components of the immune system. They are classified into three principal groups: type I, type II, and type III. (pubmed.ncbi.nlm.nih.gov)

Classification

The three interferon types use different receptor complexes. Their activities overlap, but their cellular sources, responding tissues, and predominant biological functions differ. The classification is therefore more informative than treating “interferon” as a single substance. (pmc.ncbi.nlm.nih.gov)

The receptor distinctions and type I and II membership are established features of interferon biology; the recognized type III family contains four members. IFN-λ1, IFN-λ2, and IFN-λ3 were originally also named IL-29, IL-28A, and IL-28B, respectively. (pmc.ncbi.nlm.nih.gov)

Type I interferons are major mediators of innate immunity. Many cells can produce them following detection of infection. Type II interferon, IFN-γ, is produced principally by activated T cells and natural killer cells and links innate defense with adaptive immunity. Type III interferons activate an antiviral program similar to that of type I interferons, but their effects are especially prominent in epithelial tissues, including the respiratory and intestinal barriers. This distribution reflects differences in receptor availability, not simply differences in where interferons are produced. (pubmed.ncbi.nlm.nih.gov)

Production and signaling

Recognition of infection

Interferon production and interferon action are separate processes. During infection, cellular sensors recognize microbial molecules, particularly nucleic acids in locations or forms associated with pathogens. These detection pathways activate regulatory proteins that induce interferon genes. Secreted interferon then acts on the producing cell or nearby cells that carry the appropriate receptor. This allows uninfected cells to prepare antiviral defenses before infection reaches them. (pubmed.ncbi.nlm.nih.gov)

Type I and type III interferon induction commonly follows detection of viral components. IFN-γ production is more closely associated with activation of immune cells and signals from other cytokines. Thus, sensing a pathogen, producing interferon, and responding to interferon involve distinct molecular machinery. (pubmed.ncbi.nlm.nih.gov)

The JAK–STAT pathway

The principal signaling route used by interferon receptors is the JAK–STAT signaling pathway. Receptor engagement activates associated Janus kinases, which phosphorylate STAT proteins. The activated STATs form complexes that enter the cell nucleus and regulate transcription. (pubmed.ncbi.nlm.nih.gov)

In the canonical type I pathway, JAK1 and TYK2 activate STAT1 and STAT2. These associate with interferon regulatory factor 9, IRF9, to form interferon-stimulated gene factor 3 (ISGF3). This transcription factor complex binds interferon-stimulated response elements in DNA and activates many interferon-stimulated genes (ISGs). Type III interferons use a closely related downstream program despite binding a different receptor. (pubmed.ncbi.nlm.nih.gov)

IFN-γ predominantly activates JAK1 and JAK2 and promotes formation of STAT1 homodimers. These bind DNA sequences called gamma-activated sites. Interferons can also activate additional STAT combinations and other signaling pathways, so the canonical routes do not describe every cellular response. (cshperspectives.cshlp.org)

Biological functions

Establishment of an antiviral state

Interferon-induced proteins restrict infection at several stages, including viral entry, genome replication, protein production, and release. No single induced protein accounts for the entire antiviral response; its effectiveness depends on the virus and the responding cell. (pubmed.ncbi.nlm.nih.gov)

Two well-characterized mechanisms illustrate how this response works:

• Protein kinase R (PKR) responds to double-stranded RNA and phosphorylates the translation initiation factor eIF2α. This reduces protein synthesis, restricting production of proteins needed for viral replication.
• The oligoadenylate synthetase–RNase L system responds to double-stranded RNA by generating small signaling molecules that activate RNase L. This enzyme cleaves viral and cellular RNA, contributing to inhibition of infection. (pubmed.ncbi.nlm.nih.gov)

These mechanisms act through the host cell and can affect its own RNA and protein synthesis. An antiviral state is therefore a regulated physiological response, not a process that exclusively targets viral material without consequences for the host. (pubmed.ncbi.nlm.nih.gov)

Coordination of immune responses

Interferons also influence antigen presentation and immune-cell activation. They can increase expression of major histocompatibility complex molecules, helping immune cells recognize infected or abnormal cells. IFN-γ is particularly important in activating macrophages and supporting defenses against intracellular pathogens. Interferons consequently connect cell-intrinsic protection with wider immune responses. (pubmed.ncbi.nlm.nih.gov)

Their effects on inflammation are context-dependent. Different interferon types, target cells, and accompanying signals can produce different inflammatory outcomes; “immune stimulation” alone is not an adequate description of their action. (pmc.ncbi.nlm.nih.gov)

Regulation and disease

Interferon signaling is controlled by feedback mechanisms that limit its intensity and duration. These include proteins that inhibit receptor-associated signaling and mechanisms that remove activating phosphate groups from signaling proteins. Such regulation helps balance pathogen control against tissue damage. (pubmed.ncbi.nlm.nih.gov)

Insufficient interferon responses can impair antimicrobial defense, whereas persistent or excessive signaling can contribute to chronic inflammation and autoimmunity. Interferon activity must therefore be understood in relation to the timing of infection, the affected tissue, and the broader immune environment, rather than as uniformly beneficial or harmful. (pubmed.ncbi.nlm.nih.gov)

Medical applications

Interferons are also manufactured as medicines. Their uses depend on the particular interferon and formulation; the biological family does not constitute one interchangeable treatment.

• Interferon alfa preparations, including peginterferon alfa-2a, have been used for chronic hepatitis B and hepatitis C. Pegylation attaches polyethylene glycol to the protein, prolonging its activity in the body. Interferon-based treatment had a major historical role in hepatitis C therapy, but development of oral direct-acting antivirals made interferon-free regimens possible. (medlineplus.gov)
• Interferon beta preparations are used in relapsing forms of multiple sclerosis to reduce relapses and slow disability progression; they do not cure the disease. (medlineplus.gov)
• Interferon gamma-1b is used to reduce serious infections in chronic granulomatous disease and to slow worsening of severe malignant osteopetrosis. (medlineplus.gov)

Adverse effects vary by preparation. They can include flu-like symptoms, injection-site reactions, liver abnormalities, and changes in blood-cell counts. Some interferon medicines also carry warnings about serious psychiatric or autoimmune effects. These limitations reflect, in part, their ability to alter multiple host pathways rather than a single viral target. (medlineplus.gov)

Discovery and historical development

Alick Isaacs and Jean Lindenmann described interferon in their 1957 paper Virus interference. I. The interferon. The name arose from studies of viral interference: exposure to one virus could inhibit subsequent viral infection through a host-produced factor. This work established the basis for understanding interferon as a transferable antiviral signal. (pubmed.ncbi.nlm.nih.gov)

The identification of type III interferons expanded this framework. In 2003, researchers reported IFN-λ proteins and a distinct receptor complex capable of inducing antiviral protection. This demonstrated that similar antiviral gene programs could be activated through different receptor systems, with important differences in tissue responsiveness. (pubmed.ncbi.nlm.nih.gov)

References

1. Interferons in health and diseasepubmed.ncbi.nlm.nih.gov
2. The interferons and their receptors—distribution and regulationpmc.ncbi.nlm.nih.gov
3. Regulation of type I interferon responsespubmed.ncbi.nlm.nih.gov
4. The Interferon (IFN) Class of Cytokines and the IFN Regulatory Factor (IRF) Transcription Factor Familypubmed.ncbi.nlm.nih.gov
5. Signaling through Enzyme-Linked Cell-Surface Receptorsncbi.nlm.nih.gov
6. The regulation of inflammation by interferons and their STATspmc.ncbi.nlm.nih.gov
7. The Interferon-Lambda Family Celebrates 20 Years of Scientific Discoverypmc.ncbi.nlm.nih.gov
8. IFN-Lambda (IFN-λ) Is Expressed in a Tissue-Dependent Fashion and Primarily Acts on Epithelial Cells In Vivopmc.ncbi.nlm.nih.gov
9. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infectionspubmed.ncbi.nlm.nih.gov
10. RNase L mediates transient control of the interferon response through modulation of the double-stranded RNA-dependent protein kinase PKRpubmed.ncbi.nlm.nih.gov
11. Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral responsepubmed.ncbi.nlm.nih.gov